+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Stage IIIC epithelial ovarian cancer classified solely by lymph node metastasis has a more favorable prognosis than other types of stage IIIC epithelial ovarian cancer



Stage IIIC epithelial ovarian cancer classified solely by lymph node metastasis has a more favorable prognosis than other types of stage IIIC epithelial ovarian cancer



Journal of Gynecologic Oncology 19(4): 223-228



To verify whether it can be justified to classify patients to stage IIIC epithelial ovarian cancer based on nodal involvement only. This study included all consecutive patients with stage IIIC epithelial ovarian cancer who underwent upfront cytoreductive surgery according to the FIGO guideline followed by platinum based chemotherapy from September 1989 to September 2006 at Asan Medical Center. During the study period, a total of 272 patients met the inclusion criteria. Optimal cytoreduction was achieved in 213 patients, and complete cytoreduction was achieved in 85 patients. Median follow-up time was 37 months (range, 6-181 months). The 5-year disease free survival (DFS) and overall survival (OS) rate of all patients were 23% and 57%, respectively. Forty-one patients were allocated to stage IIIC by positive nodes only. Patients with stage IIIC disease due to positive nodes only had significantly longer DFS and OS compared to other stage IIIC patients (p<0.001 and p<0.001). The DFS and OS of these patients was significantly better than those of other stage IIIC patients who achieved complete or optimal cytoreduction (p<0.001 and p<0.001). The outcome was even better than that of stage IIIA and IIIB patients (p<0.05 and p<0.05). Patients with stage IIIC epithelial ovarian cancer due to positive nodes only had a more favorable prognosis compared to other stage IIIC patients. Therefore, reevaluation of the current FIGO staging system for stage IIIC epithelial ovarian cancer is required.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055902137

Download citation: RISBibTeXText

PMID: 19471577

DOI: 10.3802/jgo.2008.19.4.223


Related references

The investigation of the factors affecting retroperitoneal lymph node metastasis in stage IIIC and IV epithelial ovarian cancer. Archives of Gynecology and Obstetrics 280(6): 939-944, 2010

Ten years survival of FIGO stage IIIC epithelial ovarian cancer cases due to lymph node metastases only. European Journal of Gynaecological Oncology 33(6): 615-616, 2013

Prognostic value of lymph node ratio in stage IIIC epithelial ovarian cancer with node-positive in a SEER population-based study. Oncotarget 7(7): 7952-7959, 2016

Ovarian cancer patients with "node-positive-only" Stage IIIC disease have a more favorable outcome than Stage IIIA/B. Gynecologic Oncology 107(1): 154-156, 2007

Survival Advantage Associated with Decrease in Stage at Detection from Stage IIIC to Stage IIIA Epithelial Ovarian Cancer. Journal of Oncology 2014: 312193, 2014

Lymph node-positive stage IIIC ovarian cancer: a separate entity?. International Journal of Gynecological Cancer 19(Suppl. 2): S18-S20, 2010

Impact of residual disease on overall survival in women with Federation of Gynecology and Obstetrics stage IIIB-IIIC vs stage IV epithelial ovarian cancer after primary surgery. Acta Obstetricia et Gynecologica Scandinavica 2018, 2018

Thomas Herzog, MD: How Do I Treat a Patient with Stage IIIC Epithelial Ovarian Cancer?. Oncology Times 33(9): 33-35, 2011

Neo-adjuvant chemotherapy in stage IIIC potentially resectable epithelial ovarian cancer. Gynecologic Oncology Reports 20: 131, 2019

The significance of paracardiac lymph-node enlargement in patients with newly diagnosed stage IIIC ovarian cancer. Gynecologic Oncology 138(2): 259-262, 2015

Impact of neoadjuvant chemotherapy on the survival of patients with stage IIIc and IV epithelial ovarian cancer. Zhonghua Zhong Liu Za Zhi 30(4): 298-301, 2008

The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer. Radiology and Oncology 50(3): 341-346, 2016

Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer. Medicine 95(36): E4797, 2017

The influence of splenic metastases on survival in FIGO stage IIIC epithelial ovarian cancer. International Journal of Gynecological Cancer 14(1): 51-56, 2004

First-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfamide in Stage IIIc ovarian epithelial cancer. European Journal of Gynaecological Oncology 25(3): 327-332, 2004